Hypertension, or high blood pressure, is a common condition that can lead to serious health issues if left uncontrolled. The National Heart Institute in Beverly Hills, California, participated in the KARDIA-2 trial, which introduced zilebesiran as a promising new treatment for patients with inadequately controlled hypertension.
Zilebesiran is an RNA interference agent and an innovative approach to managing hypertension. It targets the hepatic synthesis of angiotensinogen, the precursor of angiotensin peptides involved in blood pressure regulation.
This offers a different mechanism of action compared to traditional antihypertensive medications.
Trial Highlights
• Patient Demographics: The study included 1,500 participants with a mean age of 59 years, 43% female, and 23% with diabetes.
• Effective Results: Zilebesiran showed significant blood pressure reduction over 6 months, particularly when combined with indapamide or amlodipine.
• Safety Profile: The treatment was well tolerated, with no deaths or adverse events leading to study discontinuation.
The sustained blood pressure control observed with zilebesiran, especially alongside indapamide and amlodipine, marks a step forward in hypertension management. Its ease of use, with subcutaneous injection, could improve patient compliance and outcomes.
The KARDIA-2 trial’s findings suggest that zilebesiran could be a valuable addition to the hypertension treatment arsenal, offering new hope for patients struggling to manage their blood pressure.
Visit www.nationalheartinstitute.org to learn more and to explore other clinical trials that are currently enrolling.
CLINICAL TRIALS ARE FREE AND YOU WILL BE PAID FOR YOUR PARTICIPATION.
